MedTrace Logo

Prospective WCD Post CABG Registry (CABG Registry)

NCT06570902 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 910

Last updated 2024-11-04

No results posted yet for this study

Summary

The primary objective is to observe the rate of recovery of ventricular function (EF\>35%) after first-time coronary artery bypass graft surgery in patients who were prescribed the wearable cardioverter defibrillator (WCD) post-surgery prior to being discharged after hospitalization as part of standard clinical care.

Conditions

Interventions

DEVICE

WCD

An FDA-approved, CE marked WCD will be prescribed for up to 3 months of use after hospital discharge, with the option for longer use under physician discretion

Sponsors & Collaborators

  • Zoll Medical Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-23
Primary Completion
2029-11-30
Completion
2030-05-31
FDA Device
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06570902 on ClinicalTrials.gov